ABSTRACT
AIM: To determine kempas ability to potentiate the action of simultaneously used daklizumab. MATERIAL AND METHODS: Kempas was given to 7 patients twice: 18-21 days before transplantation and on the day of transplantation after plasmapheresis. The control group consisted of 9 patients who received induction immunodepression only with daklizumab. By demographic and clinico-laboratory parameters the groups were identical. The assessment was made by duration of the interval between administration of daklizumab. RESULTS: Patients given kempas had longer intervals between daklitumab administration (the difference was significant). CONCLUSION: Kempas potentiates an immunodepressive action of daklizumab.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antibodies, Neoplasm/therapeutic use , Immunoglobulin G/therapeutic use , Immunosuppression Therapy/methods , Immunosuppressive Agents/therapeutic use , Adolescent , Adult , Alemtuzumab , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal, Humanized , Antibodies, Neoplasm/administration & dosage , Antibodies, Neoplasm/pharmacology , Child , Child, Preschool , Daclizumab , Drug Administration Schedule , Drug Synergism , Drug Therapy, Combination , Female , Humans , Immunoglobulin G/administration & dosage , Immunoglobulin G/pharmacology , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/pharmacology , Kidney Failure, Chronic/surgery , Kidney Transplantation , Male , Treatment Outcome , Young AdultSubject(s)
Cryosurgery , Echinococcosis, Hepatic/surgery , Cryosurgery/methods , Echinococcosis, Hepatic/mortality , Echinococcosis, Hepatic/physiopathology , Hepatectomy/methods , Humans , Liver/pathology , Necrosis , Palliative Care , Postoperative Complications/epidemiology , Postoperative Complications/physiopathology , Remission Induction , Time FactorsABSTRACT
A quantitative criterion of the activation of the patient's complement during hemodialysis has been worked out on the basis of the proposed mathematical model. It has been shown that the activation of the complement system observed during hemodialysis and the negative clinical effects (leukopenia, hypoxia) accompanying it depend both on the membrane properties and the patient's individual response. A possibility has been revealed of using the above criterion for the individual choice of hemodialytic membranes in order to reduce the negative clinical effects connected with the activation of the complement system.
Subject(s)
Complement Activation , Kidney Failure, Chronic/therapy , Membranes, Artificial , Models, Biological , Renal Dialysis/instrumentation , Humans , Kidney Failure, Chronic/immunology , Mathematics , Surface PropertiesABSTRACT
One of the adverse effects of haemodialysis is activation of the complement system occurring at the contact of blood with the dialyser membrane. In vitro conditions it was found by means of a modified method of registering haemolitic complement activity pre- and post-incubation with the membrane that the activation of complement in a given blood donor depends both on the inherent complement reactivity and on the surface physico-chemical qualities. The contribution of each component was estimated by means of the coefficient of spontaneous speed (kspont) and of induced speed (kind) of complement activation. The comparison of the results of the complement system activation in vivo (in 9 dialysed patients) with the in vitro results made it possible to use the designed kinetic model in prognostication of the complement system of a given patient subjected to haemodialysis.
